<p>亞洲科技市場正在經歷顯著增長，納斯達克綜合指數等指標創下新高，而中國出口在全球貿易緊張局勢下表現出韌性。在這個動態環境中，識別有前景的科技股票需要尋找那些展現出強大創新能力和適應經濟變化的公司。</p>
<h3>亞洲十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>迅博科技</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海華測導航技術</td>
<td>25.19%</td>
<td>23.94%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>浙江藍特光學</td>
<td>21.61%</td>
<td>23.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.60%</td>
<td>57.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>31.69%</td>
<td>39.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>32.53%</td>
<td>32.58%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金迴路電子</td>
<td>26.51%</td>
<td>32.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>26.23%</td>
<td>37.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器的 174 只股票完整列表。</p>
<p>下面我們展示了一些經過篩選的股票。</p>
<h2>Essex Bio-Technology (SEHK:1061)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Essex Bio-Technology Limited 是一家投資控股公司，專注於在中國、香港及國際市場開發、生產和銷售生物藥物，市值約為 31.6 億港元。</p>
<p><strong>運營：</strong> Essex Bio-Technology 的收入主要來自其外科和眼科業務，分別為 8.799 億港元和 7.7149 億港元。該公司還提供服務，為其收入流貢獻 1842 萬港元。</p>
<p>Essex Bio-Technology 在生物科技領域展現出強勁的增長軌跡，其收入和盈利增長超過了更廣泛的香港市場。預計該公司的年收入將增長 10.2%，超過市場的 8.1% 增長率，而其盈利預計將以每年 12% 的速度增長，相比市場的 10.8%。儘管去年未能超越生物科技行業的平均水平，Essex 仍保持着良好的前景，預計股本回報率為 22.5%。此外，最近的公司動態包括股息增加和章程修訂，這可能增強治理結構和未來的股東回報。</p>
<ul>
<li>通過閲讀我們的健康報告，深入瞭解 Essex Bio-Technology 的表現。</li>
<li>通過我們的詳細歷史表現報告評估 Essex Bio-Technology 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6728b25c-0acb-4f2f-853f-a44304ab62c8/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6728b25c-0acb-4f2f-853f-a44304ab62c8/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 8 月的 SEHK:1061 收入和支出明細</p>
<h2>WuXi Xinje ElectricLtd (SHSE:603416)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> WuXi Xinje Electric Co., Ltd.專注於開發、生產和銷售工業自動化產品，業務覆蓋中國及國際市場，市值為 88.1 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要從儀器行業產生收入，報告銷售額為 17.6 億人民幣。</p>
<p>WuXi Xinje Electric 在亞洲高增長科技領域中佔據了一席之地，展現出強健的財務健康，年盈利增長為 22.8%，收入每年增長 20.3%，超過了更廣泛的中國市場 12.6% 的增長。儘管預計股本回報率為 12.9%，低於一些行業基準，但該公司在創新方面的戰略重點通過其顯著的研發投資得以體現，與其令人印象深刻的盈利軌跡相一致。最近的 2025 年第一季度財報顯示，持續的擴張努力和運營改進可能會增強其在日益競爭的電子行業中的未來表現。</p>
<ul>
<li>點擊這裏深入瞭解 WuXi Xinje ElectricLtd 的完整分析健康報告。</li>
<li>通過我們的過去報告瞭解 WuXi Xinje ElectricLtd 的歷史記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a19b6937-cbb0-46bd-81fc-c3064ac9b509/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a19b6937-cbb0-46bd-81fc-c3064ac9b509/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 8 月的 SHSE:603416 盈利和收入增長</p>
<h2>北京實驗室科技儀器 (SHSE:688056)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 北京實驗室科技儀器有限公司為全球實驗室行業製造和供應實驗室產品和解決方案，市值為 26.7 億人民幣。</p>
<p><strong>運營：</strong> 該公司專注於全球範圍內生產和交付實驗室產品和解決方案。</p>
<p>北京實驗室科技儀器在亞洲高增長科技領域中脱穎而出，年收入增長顯著，達到 20.5%，超過了更廣泛的中國市場 12.6% 的擴張率。該公司對創新的承諾通過其顯著的研發支出得以體現，預計盈利增長將以每年 28.3% 的強勁速度增長。最近的戰略收購，包括主要金融機構以 6000 萬人民幣投資 3% 股份，彰顯了對其發展軌跡和在競爭激烈的科技行業中進一步擴展運營的潛力的信心。</p>
<ul>
<li>點擊這裏通過我們的詳細分析健康報告發現北京實驗室科技儀器的細微差別。</li>
<li>通過我們的過去報告獲取北京實驗室科技儀器的歷史趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/51111a05-86d2-493b-bae2-9c04f7524ca4/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/51111a05-86d2-493b-bae2-9c04f7524ca4/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 8 月的 SHSE:688056 盈利和收入增長</p>
<h2>關鍵要點</h2>
<ul>
<li>點擊此鏈接深入瞭解我們亞洲高增長科技和人工智能股票篩選器中的 174 家公司。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>對其他可能性感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

科濟藥業-B

信捷電氣

<p>亞洲科技市場蓬勃發展，PharmaEssentia 和 CARsgen Therapeutics Holdings 等公司的增長顯著。主要參與者包括 Essex Bio-Technology，預計其收入將增長 10.2%，以及吳希電氣，收入增長達到 20.3%。北京 Labtech Instruments 也值得關注，預計其收益增長為 28.3%。整體市場展現出這些公司強大的創新能力和適應性，使它們成為高增長科技領域中有前景的投資</p>

<p>The Asian tech market is experiencing notable growth, with indices such as the Nasdaq Composite reaching new highs and Chinese exports showing resilience despite global trade tensions. In this dynamic environment, identifying promising tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic conditions.</p>
<div class="lb-trans"><p>亞洲科技市場正在經歷顯著增長，納斯達克綜合指數等指標創下新高，而中國出口在全球貿易緊張局勢下表現出韌性。在這個動態環境中，識別有前景的科技股票需要尋找那些展現出強大創新能力和適應經濟變化的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亞洲十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accton Technology</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology</td>
<td>25.19%</td>
<td>23.94%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhejiang Lante Optics</td>
<td>21.61%</td>
<td>23.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.60%</td>
<td>57.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>31.69%</td>
<td>39.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>32.53%</td>
<td>32.58%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>26.51%</td>
<td>32.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.23%</td>
<td>37.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>迅博科技</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海華測導航技術</td>
<td>25.19%</td>
<td>23.94%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>浙江藍特光學</td>
<td>21.61%</td>
<td>23.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.60%</td>
<td>57.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>31.69%</td>
<td>39.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>32.53%</td>
<td>32.58%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金迴路電子</td>
<td>26.51%</td>
<td>32.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>26.23%</td>
<td>37.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 174 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器的 174 只股票完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我們展示了一些經過篩選的股票。</p>
</div><h2>Essex Bio-Technology (SEHK:1061)</h2>
<div class="lb-trans"><h2>Essex Bio-Technology (SEHK:1061)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Essex Bio-Technology Limited is an investment holding company that develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally with a market capitalization of approximately HK$3.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Essex Bio-Technology Limited 是一家投資控股公司，專注於在中國、香港及國際市場開發、生產和銷售生物藥物，市值約為 31.6 億港元。</p>
</div><p><strong>Operations:</strong> Essex Bio-Technology generates revenue primarily from its surgical and ophthalmology segments, with HK$879.90 million and HK$771.49 million respectively. The company also provides services contributing HK$18.42 million to its revenue stream.</p>
<div class="lb-trans"><p><strong>運營：</strong> Essex Bio-Technology 的收入主要來自其外科和眼科業務，分別為 8.799 億港元和 7.7149 億港元。該公司還提供服務，為其收入流貢獻 1842 萬港元。</p>
</div><p>Essex Bio-Technology has demonstrated a robust trajectory in the biotech sector, with its revenue and earnings growth outpacing the broader Hong Kong market. The company's annual revenue is expected to increase by 10.2%, surpassing the market's 8.1% growth rate, while its earnings are forecasted to climb at an impressive rate of 12% annually, compared to the market's 10.8%. Despite not outperforming the biotech industry’s average last year, Essex maintains a promising outlook with a projected Return on Equity of 22.5%. Additionally, recent corporate developments include a dividend increase and amendments to its bylaws which could enhance governance structures and shareholder returns moving forward.</p>
<div class="lb-trans"><p>Essex Bio-Technology 在生物科技領域展現出強勁的增長軌跡，其收入和盈利增長超過了更廣泛的香港市場。預計該公司的年收入將增長 10.2%，超過市場的 8.1% 增長率，而其盈利預計將以每年 12% 的速度增長，相比市場的 10.8%。儘管去年未能超越生物科技行業的平均水平，Essex 仍保持着良好的前景，預計股本回報率為 22.5%。此外，最近的公司動態包括股息增加和章程修訂，這可能增強治理結構和未來的股東回報。</p>
</div><ul>
<li>Get an in-depth perspective on Essex Bio-Technology's performance by reading our health report here.</li>
<li>Assess Essex Bio-Technology's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的健康報告，深入瞭解 Essex Bio-Technology 的表現。</li>
<li>通過我們的詳細歷史表現報告評估 Essex Bio-Technology 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6728b25c-0acb-4f2f-853f-a44304ab62c8/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/6728b25c-0acb-4f2f-853f-a44304ab62c8/chart/revenue-and-expenses-breakdown"/></p>
<p>SEHK:1061 Revenue and Expenses Breakdown as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 SEHK:1061 收入和支出明細</p>
</div><h2>WuXi Xinje ElectricLtd (SHSE:603416)</h2>
<div class="lb-trans"><h2>WuXi Xinje ElectricLtd (SHSE:603416)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> WuXi Xinje Electric Co., Ltd. focuses on developing, producing, and selling industrial automation products both in China and internationally, with a market cap of CN¥8.81 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> WuXi Xinje Electric Co., Ltd.專注於開發、生產和銷售工業自動化產品，業務覆蓋中國及國際市場，市值為 88.1 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the instrument industry, with reported sales of CN¥1.76 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要從儀器行業產生收入，報告銷售額為 17.6 億人民幣。</p>
</div><p>WuXi Xinje Electric has carved a niche in the high-growth tech sector in Asia, demonstrating robust financial health with earnings growth of 22.8% annually and revenue surging by 20.3% each year, outpacing the broader Chinese market's growth of 12.6%. Despite a forecasted Return on Equity of 12.9%, which lags behind some industry benchmarks, the company's strategic focus on innovation is evident from its significant R&amp;D investment, aligning with its impressive earnings trajectory. Recent developments from their Q1 2025 Earnings Call highlight continued expansion efforts and operational enhancements that could bolster future performance in an increasingly competitive electronic industry landscape.</p>
<div class="lb-trans"><p>WuXi Xinje Electric 在亞洲高增長科技領域中佔據了一席之地，展現出強健的財務健康，年盈利增長為 22.8%，收入每年增長 20.3%，超過了更廣泛的中國市場 12.6% 的增長。儘管預計股本回報率為 12.9%，低於一些行業基準，但該公司在創新方面的戰略重點通過其顯著的研發投資得以體現，與其令人印象深刻的盈利軌跡相一致。最近的 2025 年第一季度財報顯示，持續的擴張努力和運營改進可能會增強其在日益競爭的電子行業中的未來表現。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of WuXi Xinje ElectricLtd.</li>
<li>Understand WuXi Xinje ElectricLtd's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 WuXi Xinje ElectricLtd 的完整分析健康報告。</li>
<li>通過我們的過去報告瞭解 WuXi Xinje ElectricLtd 的歷史記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a19b6937-cbb0-46bd-81fc-c3064ac9b509/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/a19b6937-cbb0-46bd-81fc-c3064ac9b509/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603416 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 SHSE:603416 盈利和收入增長</p>
</div><h2>Beijing Labtech Instruments (SHSE:688056)</h2>
<div class="lb-trans"><h2>北京實驗室科技儀器 (SHSE:688056)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Beijing Labtech Instruments Co., Ltd. manufactures and supplies laboratorial products and solutions to the laboratory industry worldwide, with a market capitalization of CN¥2.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北京實驗室科技儀器有限公司為全球實驗室行業製造和供應實驗室產品和解決方案，市值為 26.7 億人民幣。</p>
</div><p><strong>Operations:</strong> The company focuses on producing and delivering laboratory products and solutions globally.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司專注於全球範圍內生產和交付實驗室產品和解決方案。</p>
</div><p>Beijing Labtech Instruments is distinguishing itself in the high-growth tech landscape of Asia, with a notable annual revenue increase of 20.5%, outstripping the broader Chinese market's expansion rate of 12.6%. The firm's commitment to innovation is underscored by an impressive R&amp;D expenditure, which fuels an earnings growth forecast at a vigorous rate of 28.3% per year. Recent strategic acquisitions, including a CNY 60 million investment by major financial players for a 3% stake, underscore confidence in its trajectory and potential to scale operations further within the competitive tech sector.</p>
<div class="lb-trans"><p>北京實驗室科技儀器在亞洲高增長科技領域中脱穎而出，年收入增長顯著，達到 20.5%，超過了更廣泛的中國市場 12.6% 的擴張率。該公司對創新的承諾通過其顯著的研發支出得以體現，預計盈利增長將以每年 28.3% 的強勁速度增長。最近的戰略收購，包括主要金融機構以 6000 萬人民幣投資 3% 股份，彰顯了對其發展軌跡和在競爭激烈的科技行業中進一步擴展運營的潛力的信心。</p>
</div><ul>
<li>Click here to discover the nuances of Beijing Labtech Instruments with our detailed analytical health report.</li>
<li>Gain insights into Beijing Labtech Instruments' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的詳細分析健康報告發現北京實驗室科技儀器的細微差別。</li>
<li>通過我們的過去報告獲取北京實驗室科技儀器的歷史趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/51111a05-86d2-493b-bae2-9c04f7524ca4/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/51111a05-86d2-493b-bae2-9c04f7524ca4/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688056 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 SHSE:688056 盈利和收入增長</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Click this link to deep-dive into the 174 companies within our Asian High Growth Tech and AI Stocks screener.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們亞洲高增長科技和人工智能股票篩選器中的 174 家公司。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

亞洲高增長科技股展現出良好的發展潛力